In this episode (19:41 min), Medicom’s correspondent covers 6 presentations from the American Academy of Dermatology Annual Meeting (AAD 2022) which was held in Boston, MA, USA, 25-29 March 2022.
- Lebrikizumab improves skin lesions, pruritus, and quality of life in patients with AD
Patients treated for moderate-to-severe atopic dermatitis (AD) benefitted significantly from therapy with the IL-13 blocker lebrikizumab. Efficacy improvements were not only seen in eczema measures but also in the reduction of sleep loss and itch.
- NO-releasing gel: a novel way to fight molluscum contagiosum
A gel consisting of 2 components with a novel mode of action showed to be effective against molluscum contagiosum (MC). Almost a third of patients achieved complete clearance of all skin lesions after 12 weeks of treatment with the berdazimer 10.3% gel in the phase 3 B-SIMPLE 4 trial.
- Ruxolitinib cream demonstrates long-term efficacy in non-segmental vitiligo
The 52-weeks results of the phase 3 TRuE-V1 and TRuE-V2 trials showed that most vitiligo patients can achieve substantial repigmentation with a cream containing the topical JAK1/JAK2 inhibitor ruxolitinib. The cream was well tolerated with no clinically significant application site reactions.
- Novel anticholinergic gel is highly effective in hyperhidrosis
Topically applied sofpironium bromide gel proved to be effective and well tolerated in the phase 3 Cardigan 1 and Cardigan 2 trials including patients with primary axillary hyperhidrosis. Both subjective and objective parameters were improved with only mild anticholinergic side effects.
- Dupilumab for prurigo nodularis: a light at the end of the tunnel?
A significantly higher proportion of prurigo nodularis patients treated with dupilumab achieved a clinically meaningful amelioration of itch and disease stage compared with placebo in the phase 3 LIBERTY-PN PRIME 2 trial. Safety assessments were in line with the known dupilumab profile.
- Apremilast: A new option for recalcitrant dermatomyositis?
With an overall response rate of 87.5%, apremilast demonstrated efficacy as an add-on treatment for recalcitrant dermatomyositis without raising safety concerns. Downregulation of key signalling pathways was revealed through immunohistochemical and gene analysis.
Copyright ©2022 Medicom Medical Publishers
« Maintenance IVIG linked to fewer relapses in adults with myelin oligodendrocyte glycoprotein antibody-associated disease Next Article
Renal denervation yields meaningful and lasting BP reductions »